NCT03962296View on ClinicalTrials.gov

A Multicenter, Randomized, Double-blind Non-inferiority Trial to Evaluate the Efficacy and Safety of Entelon®

PHASE4CompletedINTERVENTIONAL
Enrollment

153

Participants

Timeline

Start Date

November 21, 2012

Primary Completion Date

January 26, 2015

Study Completion Date

January 26, 2015

Conditions
Diabetic Retinopathy
Interventions
DRUG

Vitis vinifera extract

Three daily oral doses of 50mg tablets of Vitis vinifera extract(Entelon®, Hanlim Pharm, Seoul, South Korea) were administered to patients in this group

DRUG

Calcium Dobesilate

Three daily oral doses of 50mg tablets of Calcium Dobesilate(Doxium®, Ilsung Pharm, Seoul, South Korea) were administered to patients in this group

DRUG

Placebo

Placebo tablets lacked Vitis vinifera extract or calcium dobesilate, but their appearance was identical to those of the study group tablets.

All Listed Sponsors
collaborator

Hanlim Pharm. Co., Ltd.

INDUSTRY

lead

Hanyang University

OTHER

NCT03962296 - A Multicenter, Randomized, Double-blind Non-inferiority Trial to Evaluate the Efficacy and Safety of Entelon® | Biotech Hunter | Biotech Hunter